GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
March 28, 2024 09:00 ET
|
GRI Bio, Inc.
Live webcast on Wednesday, April 3rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
March 06, 2024 09:00 ET
|
BIOXYTRAN, INC.
50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
February 27, 2024 08:30 ET
|
Imunon, Inc.
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
GeoVax Announces Multiple Patent Issuances and Allowances
February 13, 2024 09:00 ET
|
GeoVax, Inc.
Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
GRI Bio Announces Pricing of $5.5 Million Public Offering
February 02, 2024 08:00 ET
|
GRI Bio, Inc.
LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GRI Bio Announces Reverse Stock Split
January 26, 2024 08:05 ET
|
GRI Bio, Inc.
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
December 18, 2023 09:00 ET
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
December 05, 2023 09:05 ET
|
GRI Bio, Inc.
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant...
Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus
December 04, 2023 09:00 ET
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
November 27, 2023 08:35 ET
|
GRI Bio, Inc.
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to...